CIRM is accelerating stem cell therapies to patients with unmet medical needs

**Accelerating Results**
CIRM funds promising projects at any stage of research, providing them with the money they need when they need it – getting projects going within 120 days of applying.

- CIRM has funded 16 projects approved for clinical trials in disease areas including cancer, heart disease, HIV, diabetes and blood disorders. Several more therapies are expected to join that list soon.
- In addition, nine more clinical trials are underway using therapies developed from early work CIRM funded.
- CIRM funding has already resulted in almost 2,000 articles in scientific journals, advancing knowledge about all aspects of stem cell research.
- Research to date has proved that every kind of stem cell – adult, embryonic, reprogrammed (iPS) and cancer – holds potential for yielding results in treating dozens of life-threatening or life-imparing conditions.

**With Partnerships**
CIRM works as part of the project team, providing guidance and support from staff and outside experts, to increase the chances the project will be successful.

- CIRM devotes significant internal resources and leverages its vast network of world-class experts to advance the best research projects in the field.
- The partnership approach accelerates projects and increases the likelihood of success.
- The stem cell agency has created an environment across California that strongly supports both public and private sector research into life-saving and life-improving therapies.
- CIRM’s $271 million in major facilities grants helped attract an additional $543 million in funds from private donors and institutions. CIRM has turned California into a global leader in stem cell research. We have created partnerships with governments and organizations in 17 countries, one U.S. state, three international states and four foundations leveraging the best scientific minds in the world.

**Hand-in-Hand with Patients**
CIRM involves patient representatives at every stage of the process and as participants in the Clinical Advisory Panels that are part of the team once it has been funded.

- Each project is partnered with a project-specific advisory panel that includes at least one patient advisor with first hand experience of the specific condition.
- The patient advisors provide input, recommendations and the appropriate sense of urgency.
- Ten members of CIRM’s 29-member Board are patient advocates who participate in the review of grant applications and vote on final funding decisions.
- CIRM provides many learning opportunities for patients through its web site and social media and will provide speakers for public events upon request, email info@cirm.ca.gov.
Background

CIRM, California’s stem cell institute, was created by Proposition 71, a ballot measure passed by 59 percent of California voters in November 2004. The Institute is authorized to award $3 billion in state bond funds to advance stem cell research in California.

Founded: 2004
Employees: 50 employees

Leadership

Jonathan Thomas
Chair, Governing Board

Art Torres
Vice-Chair, Governing Board

C. Randal Mills
President & CEO

Our Product

Grants Awarded
As of August 2016, CIRM had awarded 757 research and facility grants to more than 70 California institutions, totaling over $2.3 billion, with more than $2 billion already dispersed to those projects.

Active programs
As of August 2016, CIRM had more than 240 active awards working with $945 million in funding.

Clinical trials
16 clinical trials funded by CIRM have been approved as have another nine using therapies developed with CIRM funding.

CIRM’s economic impact
CIRM’s grants are estimated to generate 2.3 dollars in economic activity in the state for every dollar from CIRM.

CIRM’s first $1.6 billion in grants has generated $286 million in new tax revenue for California.

CIRM has been notified of more than 180 inventions from funded projects.

How We Work

Solicit high quality projects
CIRM invites teams with high quality projects at any stage of the research cycle, from early discovery to clinical, to submit applications when their projects are ready to be taken to the next level.

Independent outside reviewers
A team of independent scientific and business experts, from outside California, reviews the applications and determines which are the most promising. Our governing Board then votes, based on the review group’s recommendations, which ones to fund.

Focus on unmet medical needs
CIRM seeks out projects that will benefit patients with significant unmet medical needs.

www.facebook.com/CaliforniaInstituteForRegenerativeMedicine
@CIRMNews
blog.cirm.ca.gov
youtube.com/CIRMTV
e-alerts: cirm.ca.gov/about-cirm/e-newsletters